INCR
InterCure Ltd.·Healthcare
0.76
0.382%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.6852W H: $1.77
InterCure Ltd.·Healthcare
NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company's closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year.
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA.